Gastric Diffuse Large B-Cell Lymphoma: A Single-Center 9-Year Experience

Couto, Maria Eduarda; Oliveira, Isabel; Domingues, Nélson; Viterbo, Luísa; Martins, António Gentil; Moreira, Ilídia; Espírito-Santo, Ana; Chacim, Sérgio; Moreira, Cláudia; Pereira, Diana; Henrique, Rui; Mariz, José

doi:10.1007/s12288-020-01391-9

Cited by 5 publications

(5 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interestingly, despite the extra-nodal nature of PG-DLBCL, it can often be of a GCB cell of origin and is unlikely to present with MYD88 mutations. [6][7][8] A non-GCB cell of origin and the presence of MYD88 mutations are features known to be associated with inferior survival, and frequently found within large B-cell lymphoma of immune-privileged sites. 8,25,26 It is important to note that while we did not perform molecular profiling, 51% of patients in our study were of a GCB cell of origin.…”

Section: -85 71-100mentioning

confidence: 99%

“…[3][4][5] According to the Hans algorithm, both a germinal centre B (GCB) cell and non-GCB cell of origin have been described, with no definitive subtype predominanting. [6][7][8][9] Further, a third will have a simultaneous low-grade component, raising the possibility of large cell transformation. 1 Historically, gastrectomy was performed; however, the contemporary approach to treatment is aligned with that of primary extra-nodal DLBCL and comprises chemoimmunotherapy with or without radiotherapy.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Primary gastric diffuse large B‐cell lymphoma: A multicentre retrospective study

Lewis,

Joy,

Jensen

et al. 2024

Br J Haematol

View full text Add to dashboard Cite

SummaryPrimary gastric diffuse large B‐cell lymphoma (PG‐DLBCL) accounts for the majority of extra‐nodal DLBCL. Even so, literature is lacking on early, localised presentations. We studied a cohort of patients with stage I disease, diagnosed between 2006 and 2018, from six centres between Australia, Canada and Denmark. Our goal was to characterise outcomes, review treatment and investigate the role of interim positron emission tomography (iPET). Thirty‐seven eligible patients were identified. The median duration of follow‐up was 42.2 months. All received chemoimmunotherapy with 91.9% (n = 34) given rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R‐CHOP). 35.1% (n = 13) underwent consolidative radiotherapy. Eighteen patients were H. pylori positive and 11 had the documentation of H. pylori eradication therapy. The 4‐year progression‐free survival and overall survival of R‐CHOP was 88% (95% CI: 71–95) and 91% (95% CI: 75–97) respectively. All patients who achieved a partial metabolic response or complete metabolic response on iPET went on to achieve complete response at the end of treatment. R‐CHOP‐based therapy with iPET assessment appears to offer favourable outcomes, with radiotherapy and H. pylori eradication therapy implemented on a case‐by‐case basis.

show abstract

Section: -85 71-100mentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Primary gastric diffuse large B‐cell lymphoma: A multicentre retrospective study

Lewis,

Joy,

Jensen

et al. 2024

Br J Haematol

View full text Add to dashboard Cite

show abstract

“… 5 At present, R‐CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone)‐like therapies represent the standard therapeutic protocol in the majority of patients, especially in people at advanced stages. 6 …”

Section: Introductionmentioning

confidence: 99%

“…The current treatments for PGI‐DLBCL involve chemotherapy, radiotherapy, surgery, and double or triple combination therapies mentioned above 5 . At present, R‐CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone)‐like therapies represent the standard therapeutic protocol in the majority of patients, especially in people at advanced stages 6 …”

Section: Introductionmentioning

confidence: 99%

“…5 At present, R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone)-like therapies represent the standard therapeutic protocol in the majority of patients, especially in people at advanced stages. 6 Although PGI-DLBCL is viewed as a potentially curable disease compared with other extranodal lymphoma types, several patients still present unfavorable outcomes and require early risk assessment. 7 A multitude of genebased signatures and biochemical markers have been considered to improve the risk assessment, while those are often unavailable and expensive.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Prognosis and complications of patients with primary gastrointestinal diffuse large B‐cell lymphoma: Development and validation of the systemic inflammation response index‐covered score

et al. 2023

View full text Add to dashboard Cite

Background This study aimed to evaluate the predictive value of systemic inflammation response index (SIRI) in primary gastrointestinal diffuse large B‐cell lymphoma (PGI‐DLBCL) patients and establish a highly discriminating risk prediction model. Methods This retrospective analysis included 153 PGI‐DCBCL patients diagnosed between 2011 and 2021. These patients were divided into a training set ( n = 102) and a validation set ( n = 51). Univariate and multivariate Cox regression analyses were conducted to examine the significance of variables on overall survival (OS) and progression‐free survival (PFS). An inflammation‐covered score system was established according to the multivariate results. Results The presence of high pretreatment SIRI (≥1.34, p < 0.001) was significantly associated with poorer survival and identified as an independent prognostic factor. Compared with NCCN‐IPI, the prognostic and discriminatory capability of the novel model SIRI‐PI showed a more precise high‐risk assessment with a higher area under the curve (AUC) (0.916 vs 0.835) and C ‐index (0.912 vs 0.836) for OS in the training cohort, and similar results were obtained in the validation cohort. Moreover, SIRI‐PI also showed good discriminative power for efficacy assessment. This new model identified patients at risk of developing severe gastrointestinal complications following chemotherapy. Conclusions The results of this analysis suggested that the pretreatment SIRI may be a potential candidate for identifying patients with a poor prognosis. And we established and validated a better‐performing clinical model, which facilitated the prognostic stratification of PGI‐DLBCL patients and can serve as a reference for clinical decision‐making.

show abstract

Complications of lymphoma in the abdomen and pelvis: clinical and imaging review

et al. 2022

View full text Add to dashboard Cite

Gastric Diffuse Large B-Cell Lymphoma: A Single-Center 9-Year Experience

Cited by 5 publications

References 18 publications

Primary gastric diffuse large B‐cell lymphoma: A multicentre retrospective study

Primary gastric diffuse large B‐cell lymphoma: A multicentre retrospective study

Prognosis and complications of patients with primary gastrointestinal diffuse large B‐cell lymphoma: Development and validation of the systemic inflammation response index‐covered score

Complications of lymphoma in the abdomen and pelvis: clinical and imaging review

Contact Info

Product

Resources

About